Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.
Zacks·7h ago
More News
J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs
The company will also provide U.S. Medicaid programs access to medicines at prices comparable to those in other developed countries.
Stocktwits·5d ago
Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up
DNLI maps 2026 goals as it awaits FDA action on tividenofusp alfa, targeting first commercial validation amid multiple late-stage readouts.
Zacks·6d ago
Sanofi (NASDAQ:SNY) Lowered to Equal Weight Rating by Barclays
Barclays downgraded Sanofi from an "overweight" rating to an "equal weight" rating in a research report on Tuesday...
MarketBeat·7d ago
Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings?
Galafold drives over 80% of Amicus product revenues, with $371.5M in the first nine months of 2025 sales as investors await Q4 sales performance.
Zacks·7d ago
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine
Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.
Zacks·7d ago
Augustine Asset Management Inc. Has $2.13 Million Holdings in Sanofi $SNY
Augustine Asset Management Inc. reduced its stake in Sanofi (NASDAQ:SNY - Free Report) by 41.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned...
MarketBeat·8d ago
Flu Season's Here This Dividend-Payer Controls the Shot Market
With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket...
MarketBeat·8d ago
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
Zacks·8d ago
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.